Preview

Медицинский Совет

Расширенный поиск

УРАТСНИЖАЮЩАЯ ТЕРАПИЯ ПОДАГРЫ: ОСНОВНЫЕ ПРИНЦИПЫ И РЕАЛЬНЫЕ ВОЗМОЖНОСТИ

https://doi.org/10.21518/2079-701X-2017-20-144-150

Полный текст:

Аннотация

Ключевым медикаментозным методом лечения подагры является уратснижающая терапия, назначение которой в клинической практике сопряжено с высокой вероятностью ошибок из-за незнания показаний к ней, принципов выбора и правил назначения конкретных препаратов. В статье обсуждены показания к уратснижающей терапии у пациентов с подагрой, цели такой терапии, приведены данные о доступных в РФ уратснижающих препаратах (аллопуринол, фебуксостат).

Об авторе

М. С. Елисеев
Научно-исследовательский институт ревматологии им. В.А. Насоновой.
Россия

кандидат медицинских наук.

Москва. 



Список литературы

1. Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры – научно обоснованное требование улучшения трудового и жизненного прогноза больных. Научнопрактич. ревматол., 2004; 1: 5-7.

2. Елисеев М.С. Алгоритм диагностики и лечения подагры. РМЖ, 2015, 23(7): 410-414.

3. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum, 2004, 51(3): 321-5.

4. Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis, 2016, 0: 1–14.

5. Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis, 2012, 71: 1765-1770.

6. Kuo CF, Grainge MJ, Mallen C et al. Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA, 2014, 312(24): 2684-6.

7. Jordan KM, Cameron JS, Snaith M et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford), 2007, 46: 1372-4.

8. Елисеев МС. Подагра. Ревматология. Клиничес кие российские рекомендации. М.: Геотар, 2017: 253-264.

9. Bose B, Badve SV, Hiremath SS et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant, 2014, 29: 406-413.

10. Krishnan E, Svendsen K, Neaton JD et al. Longterm cardiovascular mortality among middle aged men with gout. Arch Intern Med, 2008, 168: 1104-1110.

11. Higgins P, Dawson J, Lees KR et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and metaanalysis. Cardiovasc Ther, 2012, 30: 217-226.

12. Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: asystematic review and meta-analysis. J Clin Hypertens (Greenwich), 2013, 15: 435-442.

13. Елисеев М.С., Барскова В.Г., Денисов И.С. Динамика клинических проявлений подагры у мужчин (данные 7-летнего ретроспективного наблюдения). Терапевтический архив, 2015, 87(5): 10-15.

14. Chan EC, House ME, Petrie KJ et al. Complementary and alternative medicine use in patients with gout. The longitudinal observational study. J Clin Rheumatol, 2013, 20: 16-20.

15. Neogi T. Clinical practice. Gout. N. Engl. J. Med., 2011, 364: 443-52.

16. Eminaga F, Le-Carratt, Jones A, Abhishek A. Does the initiation. of urate-lowering treatment during an acute gout attack prolong the current episode and precipitate recurrent attacks: a systematic literature review. Rheumatol Int, 2016, 36: 1747-52.

17. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: Analysis from managed care data. J. Clin. Rheumatol., 2006, 12(2): 61-65.

18. Silva L, Miguel ED, Peiteado D et al. Compliance in gout patients. Acta Reumatol. Port., 2010, 35(5): 466-74.

19. Khanna D, Fitzgerald J, Khanna P et al. 2012 American College of Rheumatology Guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken), 2012, 64: 1431-1446.

20. Stamp L, Merriman T, Barclay M et al. Impaired response or insufficient dosage? Examining the potential causes of ‘inadequate response’ to allopurinol in the treatment of gout. Semin Arthritis Rheum, 2014, 44: 170-174.

21. Ryu H, Song R, Kim H et al. Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol, 2013, 53: 211–216.

22. Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimi zing the risk. Nat Rev Rheum. 2016, 12: 235-42.

23. Stamp LK, Chapman PT, Barclay ML et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis, 2017, 0: 1-7.

24. Stamp L, Taylor W, Jones P et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum, 2012, 64: 25292536.

25. Swan S, Khosravan R, Mauer MD et al. Effect of renal impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat (TMX67), a novel non-purine, selective inhibitor of xanthine oxidase. Arthr Rheum, 2003, 48(Suppl. 9): 529.

26. Shibagaki Y, Ohno I, Hosoya T, Kimura K. Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertens Res, 2014, 37(10): 919-25.

27. Whelton A, MacDonald PA, Chefo S, Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med, 2013, 125(1): 106-14.

28. Sircar D, Chatterjee S, Waikhom R et al. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Am J Kidney Dis, 2015, 66(6): 945-50.

29. Echteld IA, Durme C, Falzon L et al. Treatment of Gout Patients with Impairment of Renal Function: A Systematic Literature Review. J Rheum. Suppl., 2014, 92: 48-54.

30. Becker MA Schumacher H, Wortmann R et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med, 2005, 353: 2450-2461.

31. Becker M, Schumacher H Jr, Wortmann R et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, phase II, randomized, double-blind, placebocontrolled, doseresponse clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum, 2005, 52: 916–923.

32. Schumacher H, Becker M, Wortmann R et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemiaand gout: a 28-week, phase III, randomized, doubleblind, parallel-group trial. Arthritis Rheum, 2008, 59: 1540-1548.

33. Love BL, Barrons R, Veverka A, Snider KM. Urate-lowering therapy for gout: Focus on febuxostat. Pharmacotherapy, 2010, 30: 594– 608.

34. Calogiuri G, Nettis E, Di Leo E et al. Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules. Inflamm Allergy Drug Targets, 2013, 12: 19-28.

35. Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol, 2011, 38: 1957-1959.


Для цитирования:


Елисеев М.С. УРАТСНИЖАЮЩАЯ ТЕРАПИЯ ПОДАГРЫ: ОСНОВНЫЕ ПРИНЦИПЫ И РЕАЛЬНЫЕ ВОЗМОЖНОСТИ. Медицинский Совет. 2017;(20):144-150. https://doi.org/10.21518/2079-701X-2017-20-144-150

For citation:


Eliseev M.S. PNEUMOCYSTIC PNEUMONIA IN RHEUMATIC DISEASES: CURRENT ISSUES IN PROPHYLAXIS. Medical Council. 2017;(20):144-150. (In Russ.) https://doi.org/10.21518/2079-701X-2017-20-144-150

Просмотров: 255


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)